With some help from there humans, Houston pets can get virtual care through a Texas startup. Image courtesy of TeleVet

A Texas-based, digitally optimized company focused on veterinary care is helping pet owners connect with medical professionals from the comfort of their homes, offsetting the impact of the social distancing measures to reduce the spread of COVID-19.

TeleVet Inc., which is based in Austin but is used by local veterinarians, recently announced that they will be providing their animal telemedicine platform free for one month to provide essential animal healthcare, connecting animal patients to veterinarians all over the country. TeleVet is used across 1,000 clinics and is accessible on phone, tablet, or computer.

The free month will be provided to cities that have been hard-hit by the virus such as New York City, Atlanta, New Orleans, San Francisco, Seattle, Miami, Las Vegas, and Chicago.

"In some cases, clinics in impacted cities are having to suddenly shut down or doing drop off visits," Steven Carter, co-founder, and CEO of TeleVet, tells InnovationMap. "We see that telemedicine is a huge component to keeping their staff and their client base during a time when social distancing is critical to flattening the curve of coronavirus cases."

Houston-area vet Amy Garrou and the other vets in her practice have been using TeleVet for several months before the outbreak of the virus. Before the platform, animal patients and their owners had to come into the office for post-surgery check-ups or other outpatient procedures. Garrou says her practice has been increasing the number of patients who use the platform since before the social distancing measures, making it a part of their daily workflow.

"We can check for infections such as ear infections or drainage from either a still picture or a video, or even a live video conference with the owner," says Garrou. "The platform has been useful because we can do any of those consultations and get the information we need to manage the case without the pet owner having to come into the clinic."

In January, TeleVet closed a $2 million seed round with investments from Houston-based Mercury Fund and Nebraska-based Dundee Venture Capital. (Amy Garrou is the wife of Mercury Fund Managing Director Blair Garrou.) According to the company's LinkedIn page, TeleVet is hiring.

Since being founded in 2015, the company has become a U.S. market leader in animal telemedicine. Over the last few years, telemedicine has been quickly expanding, and during the coronavirus outbreak, there has been a greater rush to move towards providing telemedicine for humans as well as pets.

"We realized that a lot of stuff can be solved remotely, keeping the client and the pet at home so that the staff does not have to physically interact with the client which offers convenience to both the client and the vet," says Carter.

Vets like Garrou say TeleVet helps them streamline the process by syncing with their medical records software seamlessly. This cuts costs and saves time from administrative duties. This also allows pet-owners to have access to medical notes regarding the health of their pet.

Her office is thinking of offering a curbside pick up service where they use TeleVet to communicate with pet owners to provide a contactless vet visit. A medical professional with personal protection equipment meets them in the parking lot and escorts the pet inside the vet's office where they use live video feed during the consultation so the owner can continue to be part of the process.

"It's proved to be really vital, especially in those cities where there's a complete shutdown," says Garrou. "The number of people that are realizing they've got to do something in this environment to keep their businesses afloat is rising."

As reliance on telemedicine increases due to the crisis, Garrou says it will eventually become part of the options available for pet owners, and especially vets who work long hours and tend to suffer from high levels of stress and burnout.

"We're really focused on helping, not only just to keep vets' businesses afloat right now," says Carter. "We can't stress enough that we care about the individuals in those practices. We want to help vets with work-life balance and reduce the burnout rate."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.